[A18-19] Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 15.06.2018
Commission awarded on 15.03.2018 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia
Added benefit not proven for any of the three research questions due to a lack of relevant study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A21-171||Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2018-09-06 A G-BA decision was published.